The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-25 and is reviewed periodically as new material appears.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic peptide | Melanocortin receptor agonist family |
| Molecular weight | Approximately 1025 Da | Free base form |
| Appearance | White to off-white powder | Lyophilized product |
| Solubility | Soluble in water | Also dissolves in polar organic solvents |
| Storage temperature | -20 degrees Celsius | Dry and protected from light |
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
{\displaystyle {\begin{aligned}{\frac {\mathbf {D} m}{\mathbf {Dt} }}&={\iiint \limits _{V}}\left({{\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot \mathbf {u} )}\right)dV\\{\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot {\mathbf {u} })&={\frac {\partial \rho }{\partial t}}+({\nabla \rho })\cdot {\mathbf {u} }+{\rho }(\nabla \cdot \mathbf {u} )={\frac {\partial \rho }{\partial t}}+\nabla \cdot ({\rho \mathbf {u} })=0\end{aligned}}}
=== Religious opposition === A number of religious sects prohibit organ donation. Ultra-Orthodox Jews oppose post mortem organ donation, and have tried to pass laws against unclaimed cadavers being used in research. A number of religious organizations, including Catholic and Jewish ones, object to the display of plastinated body parts at public exhibitions.
If the metabolite only takes the right side new labeling patterns can occur, all in equal proportion. Other proportions can occur depending on how much of the original metabolite follows the left side of the pathway versus the right side of the pathway. Here the proportions are shown for a situation in which half of the metabolites take the left side and half the right, but other proportions can occur. These patterns of labeled atoms and unlabeled atoms in one compound represent isotopomers. By measuring the isotopomer distribution of the differently labeled metabolites, the flux through each reaction can be determined. MFA combines the data harvested from isotope labeling with the stoichiometry of each reaction, constraints, and an optimization procedure resolve a flux map. The irreversible reactions provide the thermodynamic constraints needed to find the fluxes. A matrix is constructed that contains the stoichiometry of the reactions. The intracellular fluxes are estimated by using an iterative method in which simulated fluxes are plugged into the stoichiometric model. The simulated fluxes are displayed in a flux map, which shows the rate of reactants being converted to products for each reaction. In most flux maps, the thicker the arrow, the larger the flux value of the reaction.
=== Candice Allbright === Candice Allbright (Alexandra Moen) is Eric's wife, with whom he has two daughters. She and Eric share a profane sense of humor. She later divorces Eric between series 2 and 3. In series 4, Candice and Eric learn that their daughter Lily has been expelled from school for catfishing another student; Candice blames Lily's behavioral issues on Eric's absence as a father. Eric lets Candice and Lily stay at the hotel suite serving as the office of SternTao, his hedge fund with Harper. Candice tells Eric not to "confuse regret with love."
== Description == S. affinis is a perennial herbaceous plant with red to purple flowers and reaches a height of 30–120 centimetres (12–47 in). The green leaves are opposite arranged on the stem. The rough, nettle-like leaves can be ovate-cordate shaped with a width of 2.5–9.5 cm (1–3+3⁄4 in) or ovate-oblong with a width of 1.5–3.5 cm (5⁄8–1+3⁄8 in). The leaves are separated into a leaf blade and a petiole. The petiole has a length of 1–2 cm (3⁄8–3⁄4 in) and becomes shorter towards the stem apex. Similar to the potato, S. affinis grows rhizomes which are approximately 8 cm (3+1⁄8 in) long and 2 cm (3⁄4 in) thick. By medullary primary growth they thicken primarily on the internodes and less on the nodes. This way at irregular intervals constricted tubers are formed, which are usually thinner on both ends. The tubers are covered with a thin, pale-beige-to-ivory skin. The flesh underneath is white and tender.
Sources: en.wikipedia.org
=== 1997–1999: Early career === During the 1997 season, Helton hit for a .280/.337/.484 slash line, with five home runs, in 35 games. After the season, the Rockies were left facing a major dilemma. Incumbent first baseman Andrés Galarraga was still highly productive and tremendously popular among the fan base, while Helton had shown that he was clearly ready to replace him as the team's first baseman. The Rockies controversially opted to let the 36 year old Galarraga go; he signed a three year deal with the Atlanta Braves and had a monster year, although he missed the entire season thereafter after being diagnosed with non-Hodgkin's lymphoma, before returning in year three to post another highly successful season. Meanwhile, Helton replaced him as the full-time starter at first base, thus beginning his 15 year tenure as the team's regular first baseman, starting with that 1998 season. The Rockies named Helton their club representative in 1998, the first time the team had ever given that role to a rookie. (Helton's 1997 playing time was sufficiently limited so that he retained rookie status in 1998.) Helton slashed .315/.380/.530, with 25 home runs and 97 RBI, in 152 games. He led all rookies in average (.315), home runs (25), RBI (97), multi-hit games (49), total bases (281), slugging percentage (SLG) (.530) and extra base hits (63). He also led all National League (NL) rookies in runs (78), hits (167) and on-base percentage (.380).
Some employees had split their time between the two companies. SVB Financial Group began exploring a potential sale of the bank's sister companies SVB Capital and SVB Securities. The latter's founder, Jeffrey Leerink, expressed interest in buying back the firm. However, the finances of these companies are deeply intertwined with Silicon Valley Bank, which could complicate any sale. The company filed Chapter 11 bankruptcy one week after the bank's failure. A group including Centerbridge Partners, Davidson Kempner Capital Management, and PIMCO reportedly bought a stake in the company in anticipation of the bankruptcy. According to FDIC chairman Martin J. Gruenberg, the estimated cost to the Deposit Insurance Fund to cover the bank's collapse was $20 billion – including $18 billion to cover uninsured deposits.
In epilepsy, abnormal electrical activity in the brain can cause seizures. In multiple sclerosis, the immune system attacks the nerve linings, damaging the nerves' ability to transmit signals. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a motor neuron disease which gradually reduces movement in patients. There are also many other diseases of the nervous system.
Phosphatidylinositol kinases phosphorylate phosphatidylinositol species, to create species such as phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2), phosphatidylinositol 3,4,5-trisphosphate (PIP3), and phosphatidylinositol 3-phosphate (PI3P). The kinases include phosphoinositide 3-kinase (PI3K), phosphatidylinositol-4-phosphate 3-kinase, and phosphatidylinositol-4,5-bisphosphate 3-kinase. The phosphorylation state of phosphatidylinositol plays a major role in cellular signalling, such as in the insulin signalling pathway, and also has roles in endocytosis, exocytosis and other trafficking events. Mutations in these kinases, such as PI3K, can lead to cancer or insulin resistance. The kinase enzymes increase the rate of the reactions by making the inositol hydroxyl group more nucleophilic, often using the side chain of an amino acid residue to act as a general base and deprotonate the hydroxyl, as seen in the mechanism below. Here, a reaction between adenosine triphosphate (ATP) and phosphatidylinositol is coordinated. The end result is a phosphatidylinositol-3-phosphate as well as adenosine diphosphate (ADP). The enzymes can also help to properly orient the ATP molecule, as well as the inositol group, to make the reaction proceed faster. Metal ions are often coordinated for this purpose.
Although higher energies can produce more astatine-211, it will produce unwanted astatine-210 that decays to toxic polonium-210 as well. Instead, the maximum energy of the particle accelerator is set to be below or slightly above the threshold of astatine-210 production, in order to maximize the production of astatine-211 while keeping the amount of astatine-210 at an acceptable level.
Sources: en.wikipedia.org
=== Bioengineering === The subfield of bioengineering concentrates on creating novel metabolic and regulatory pathways, and is currently the one that likely draws the attention of most researchers and funding. It is primarily motivated by the desire to establish biotechnology as a legitimate engineering discipline. When referring to this area of synthetic biology, the word "bioengineering" should not be confused with "traditional genetic engineering", which involves introducing a single transgene into the intended organism. Bioengineers adapted synthetic biology to provide a substantially more integrated perspective on how to alter organisms or metabolic systems. A typical example of single-gene genetic engineering is the insertion of the human insulin gene into bacteria to create transgenic proteins. The creation of whole new signalling pathways, containing numerous genes and regulatory components (such as an oscillator circuit to initiate the periodic production of green fluorescent protein (GFP) in mammalian cells), is known as bioengineering as part of synthetic biology. By utilising simplified and abstracted metabolic and regulatory modules as well as other standardized parts that can be combined to create new pathways or creatures, bioengineering aims to create innovative biological systems. In addition to creating opportunities for novel applications, this strategy is anticipated to make bioengineering more predictable and controllable than traditional biotechnology.
Mick Anglo (born Maurice Anglowitz, 19 June 1916 – 31 October 2011) of Russian Jewish ancestry, was a British comic book writer, editor and artist, as well as an author. He is best known for creating the superhero Marvelman, later known as Miracleman, a character later revived in 1982 in a dark, post-modern reboot by writer Alan Moore, with later contributions by Neil Gaiman. Lisa Appignanesi (born 4 January 1946) writer, novelist, campaigner for free expression; was Chair of the Royal Society of Literature; former President of English PEN; Chair of Freud Museum; chaired 2017 Booker International Prize; Honorary Fellow of St Benet's Hall, Oxford and visiting professor in the Department of English at King's College London, and held a Wellcome Trust; has written for The New York Review of Books, The Guardian and The Observer, as well as making programmes and appearing on the BBC; was Director of Talks and Seminars at the Institute of Contemporary Arts (ICA) in London; was made a Chevalier of the Ordre des Arts et des Lettres and was appointed Officer of the Most Excellent Order of the British Empire (OBE) in the 2013 New Year Honours for services to literature. She became a Fellow of the Royal Society of Literature in 2015 and became the Chair of the Royal Society of Literature Council in 2016. Neal Ascherson (born 5 October 1932) journalist and writer; described by Radio Prague as "one of Britain's leading experts on central and eastern Europe".
LigoLab Information System is an American software company that provides software and laboratory operating systems for clinical laboratories. LigoLab develops and distributes the software tool TestDirectly, which is used for COVID-19 testing. It is based in Glendale, California.
Starting with the work of Carl Woese from 1977, genomics studies have placed the last universal common ancestor (LUCA) of all modern life-forms between Bacteria and a clade formed by Archaea and Eukaryota in the phylogenetic tree of life. It lived over 4.2 Gya. A minority of studies have placed the LUCA in Bacteria, proposing that Archaea and Eukaryota are evolutionarily derived from within Eubacteria; Thomas Cavalier-Smith suggested in 2006 that the phenotypically diverse bacterial phylum Chloroflexota contained the LUCA.
Olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder as well as treatment-resistant depression.
Sources: en.wikipedia.org
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.
It emerged from research on melanotan II. Investigators exploring derivatives observed distinct pharmacological features related to sexual function.
Common names include bremelanotide and PT-141. Chemical databases may also list early development codes and descriptive names.
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.